Filtered By:
Nutrition: Vitamin K

This page shows you your search results in order of relevance. This is page number 20.

Order by Relevance | Date

Total 1818 results found since Jan 2013.

Management of stroke in patients on antithrombotic therapy: Practical issues in the era of direct oral anticoagulants
Rev Neurol (Paris). 2021 Oct 20:S0035-3787(21)00707-4. doi: 10.1016/j.neurol.2021.07.021. Online ahead of print.ABSTRACTAntithrombotic drugs (ADs) are the mainstay of secondary prevention of thrombotic vascular diseases. Management of patients under long-term treatment with ADs admitted for acute cerebrovascular disease, either ischemic stroke (IS) or intracerebral hemorrhage (ICH), has become a frequent situation that might influence decision-making processes from diagnosis to therapeutic strategies. The aim of this review is to summarize current data from the literature to help clinicians in their decisions for stroke ca...
Source: Revue Neurologique - October 24, 2021 Category: Neurology Authors: I Sibon J S Liegey Source Type: research

Intravenous Thrombolytic Therapy for Treatment of Acute Ischemic Stroke in Patients Taking NOACs
Intravenous thrombolytic therapy with recombinant tissue plasminogen activator (alteplase) is the cornerstone of acute ischemic stroke reperfusion therapy and is associated with significant improvements in outcomes. Historically, a number of exclusion criteria for use of alteplase had been in place, but over the past 20 years, some of these have been eliminated (eg, age>80 years, seizures at stroke onset) or have become less stringent (eg, exclusion criteria may not strictly apply to recent vitamin K antagonist treatment if the patient has an international normalized ratio<1.7, and treatment may be administered in an...
Source: JAMA - February 22, 2022 Category: General Medicine Source Type: research

Left atrial appendage closure for stroke prevention in nonvalvular atrial fibrillation: A current overview
J Cardiol. 2022 Nov 15:S0914-5087(22)00277-5. doi: 10.1016/j.jjcc.2022.11.006. Online ahead of print.ABSTRACTAtrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice and its prevalence increases with age. AF causes palpitations, heart failure, and cardiogenic embolism. Of them, the most critical and fatal complication is a cardio-embolic event. Oral anticoagulation plays a central role in reducing stroke risk in AF patients. Recently, when oral anticoagulation is considered in patients with non-valvular AF who are eligible for direct oral coagulations, they are preferred to vitamin K antagoni...
Source: Journal of Cardiology - November 18, 2022 Category: Cardiology Authors: Hiroshi Ueno Teruhiko Imamura Shuhei Tanaka Nobuyuki Fukuda Koichiro Kinugawa Source Type: research

DOACs or Vitamin K Antagonists for Patients ≥ 85 With AF and Recent Stroke? DOACs or Vitamin K Antagonists for Patients ≥ 85 With AF and Recent Stroke?
Until recently, clinicians had little evidence to guide their decisions about the most effective and safe treatment for the oldest patients with atrial fibrillation and recent stroke.Medscape Medical News
Source: Medscape Internal Medicine Headlines - January 3, 2023 Category: Internal Medicine Tags: Cardiology News Source Type: news

Safety and effectiveness of rivaroxaban for prevention of stroke in patients with nonvalvular atrial fibrillation: analysis of routine clinical data from four countries
CONCLUSIONS: Incidences of intracranial bleeding were generally lower with rivaroxaban than with SOC, whereas incidences of gastrointestinal and urogenital bleeding were generally higher. The safety profile of rivaroxaban for NVAF in routine practice is consistent with findings from randomized controlled trials and other studies.PMID:36795067 | DOI:10.1080/14740338.2023.2181334
Source: Expert Opinion on Drug Safety - February 16, 2023 Category: Drugs & Pharmacology Authors: Luis Alberto Garc ía-Rodríguez Ana Ruig ómez Tania Schink Annemarie Voss Elisabeth Smits Karin M A Swart Yanina Balabanova Kiliana Suzart-Woischnik Gunnar Brobert Ron M C Herings Source Type: research

Non-major bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention with atrial fibrillation: a systematic review and network meta-analysis
ConclusionsBased on current evidence, for stroke prevention in patients with AF, the safest DOAC is apixaban in terms of non-major bleeding. This suggests that apixaban may have a lower risk of non-major bleeding than other anticoagulants and may help provide some clinical reference for choosing a more appropriate drug for the patient.
Source: European Journal of Clinical Pharmacology - June 13, 2023 Category: Drugs & Pharmacology Source Type: research

Survey on APS diagnosis and antithrombotic treatment in patients with ischaemic stroke, other brain ischaemic injury or arterial thromboembolism in other sites: Communication from ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies (LA/aPL)
CONCLUSIONS: Much of the variation in practice reflects the lack of evidence-based recommendations. The survey results should inform the development of a more uniform multidisciplinary consensus approach to diagnosis and antithrombotic treatment.PMID:37391096 | DOI:10.1016/j.jtha.2023.06.020
Source: Thrombosis and Haemostasis - June 30, 2023 Category: Hematology Authors: Hannah Cohen David J Werring Arvind Chandretheva Prabal Mittal Katrien M J Devreese David A Isenberg ISTH SSC LA/aPL Subcommittee Study Group Source Type: research

Vitamin K Antagonists-Associated Cerebral Hemorrhages: What Are Their Characteristics? Original Contributions
Conclusions— A similar anatomic distribution of ICH in patients with or without VKAs suggests that VKAs should not be considered as a cause of ICH because both locations are usually due to different vasculopathies (deep perforating arteries vasculopathy in deep and cerebral amyloid angiopathy in lobar). The different impact of VKAs on ICH volumes according to location suggests a different susceptibility of these vasculopathies to VKAs. This finding may lead to specific therapeutic strategies.
Source: Stroke - January 18, 2013 Category: Neurology Authors: Dequatre-Ponchelle, N., Henon, H., Pasquini, M., Rutgers, M. P., Bordet, R., Leys, D., Cordonnier, C. Tags: Cerebrovascular disease/stroke, Intracerebral Hemorrhage Original Contributions Source Type: research

End of Study Transition From Study Drug to Open-Label Vitamin K Antagonist Therapy: The ROCKET AF Experience Original Articles
Conclusions— The excess of events at EOS was likely because of a period of inadequate anticoagulation in rivaroxaban participants switched to vitamin K antagonist therapy. If transition from rivaroxaban to vitamin K antagonist is needed, timely monitoring and careful dosing should be used to ensure consistent and adequate anticoagulation.
Source: Circulation: Cardiovascular Quality and Outcomes - July 16, 2013 Category: Cardiology Authors: Mahaffey, K. W., Hellkamp, A. S., Patel, M. R., Hannan, K. L., Schwabe, K., Nessel, C. C., Berkowitz, S. D., Halperin, J. L., Hankey, G. J., Becker, R. C., Piccini, J. P., Breithardt, G., Hacke, W., Singer, D. E., Califf, R. M., Fox, K. A. A. Tags: Platelet function inhibitors, Arrhythmias, clinical electrophysiology, drugs, Embolic stroke, Anticoagulants Original Articles Source Type: research

Inadequate anticoagulation by Vitamin K antagonists and major adverse cardiovascular events other than stroke
I read the article by Pastori et al. [1] with great interest. In their artcile, the authors reported that inadequate anticoagulation by Vitamin K Antagonists was found to be associated with Major Adverse Cardiovascular Events (MACE) in patients with atrial fibrillation, and they concluded that time in therapeutic range (TTR) was an independent predictor of MACE in patients with atrial fibrillation. It is known that inadequate anticoagulation by Vitamin K Antagonists is a strong predictor of stroke.
Source: International Journal of Cardiology - October 30, 2015 Category: Cardiology Authors: Mehmet Eyuboglu Tags: Correspondence Source Type: research

Quality and predictors of anticoagulant control with vitamin K antagonist for stroke prevention in atrial fibrillation.
PMID: 27307147 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - June 15, 2016 Category: Hematology Authors: Wilson MR, Parakramawansha R, Quinn TJ, Tait RC Tags: Thromb Haemost Source Type: research

Stroke Risk Stratification Schemes in Atrial Fibrillation in the Era of Non-Vitamin K Anticoagulants: Misleading and Obsolete, at least for the Low-Risk Patients?
Abstract The thromboembolic risk of atrial fibrillation (AF) is significantly mitigated by oral anticoagulation (OAC) therapy, albeit at an increasing bleeding risk. The general principle is that the expected protective benefit of OAC must not exceed the potential harm conferred by possible bleeding. Over the recent years, the CHA2DS2-VASc score has been proven to be superior to other scores in identifying 'low risk' AF patients. However, even this latest score does not incorporate all possible risk factors causing a high thromboembolic risk, while the individual components of the CHA2DS2-VASc score do not seem to...
Source: Current Drug Targets - September 4, 2016 Category: Drugs & Pharmacology Authors: Manolis AS, Manolis TA, Manolis AA, Melita H Tags: Curr Drug Targets Source Type: research

Analysis of The Costs Associated with Vitamin K Antagonist Treatment for Stroke Prevention in Non Valvular Atrial Fibrialltion in Mexico
The objective of this research was to quantify the collective costs of VKA treatment for patients with non-valvular atrial fibrillation (NVAF) in Mexico.
Source: Value in Health - October 29, 2016 Category: Global & Universal Authors: J Briere, K Bowrin, R Wood, T Holbrook, J Roberts Source Type: research